Line 13 includes $14,000 paid to Unravel Biosciences for scientific services to generate datasets to support drug repurposing and potentially development. This represents the first payment, the second of which will be due in 2025.
Main program · fiscal year 2024
In 2024, CURE5 raised $192k to advance research and therapeutic development for CDKL5 Deficiency Disorder. The Foundation paid $14k to Unravel Biosciences which provided specialized scientific services supporting preclinical research. Specifically, Unravel Biosciences leveraged its AI-driven RNA analysis for a rapid drug repurposing screen. The data collected will be used in partnership with other… Read more
In 2024, CURE5 raised $192k to advance research and therapeutic development for CDKL5 Deficiency Disorder. The Foundation paid $14k to Unravel Biosciences which provided specialized scientific services supporting preclinical research. Specifically, Unravel Biosciences leveraged its AI-driven RNA analysis for a rapid drug repurposing screen. The data collected will be used in partnership with other CURE5 grantees. In addition, the Foundation designed and launched its grantmaking framework, identified research collaborators, and initiated planning for larger research grants to be awarded in 2025. These activities represent the Foundation's first year of programmatic operations in pursuit of its exempt purpose of supporting scientific discovery and treatments for CDKL5 Deficiency Disorder. The principal project funded in 2025 will be an iPSC portfolio with Boston Children's and building on our repurposing work with several other partners.
$14,000 spent
In the organization's own words to the IRS, shown for context. None of this affects the America's Best Score, and a Form 990 describes programs without measuring their results.
Tax filings by year
Financial data extracted from the Form 990 the organization filed with the IRS for each fiscal year. Revenue lines can exceed 100% when other items, such as fundraising event costs, are netted against total revenue.
Revenue$192,305Fiscal year 2024
Expenses$14,000Fiscal year 2024
Total assets—Fiscal year 2024
Total liabilities—Fiscal year 2024
Fiscal year ending December2024
Revenue$192,305
Expenses$14,000
Net income$178,305
Net assets$178,305
Notable sources of revenue
Percent of total revenue
Contributions
$192,305
100.0%
Program services
$0
0.0%
Investment income
$0
0.0%
Other (net)
$0
0.0%
Assets / debt
Total assets
—
Total liabilities
—
Net assets
$178,305
Compensation
Not in our extract for this year.
Fiscal year ending December2023
Revenue$0
Expenses$0
Net income$0
Net assets$0
Notable sources of revenue
Percent of total revenue
Contributions
$0
—
Program services
$0
—
Investment income
$0
—
Other (net)
$0
—
Assets / debt
Total assets
—
Total liabilities
—
Net assets
$0
Compensation
Not in our extract for this year.
About this data
Figures come from IRS Form 990 filings, through the IRS Exempt Organizations Business Master File (2026-11-09) and e-filed returns. Form 990 data typically lags 12–24 months behind an organization's fiscal year. Found an error?